Back

Press Release: ALTURiX Introduces CEYESTO Melatonin Oral Solution In The UK Featuring A Diverse Set Of Approved Indications – Two Of Which Are World-First

Issued: London, Wednesday 25th October 2023

Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has launched CEYESTO® 1mg/ml Melatonin Oral Solution in the UK, having been granted a broad range of licensed indications by the MHRA – two of which are world-first1. In addition, use across a wide range of different age groups has been granted1.

The UK melatonin market is currently complicated by the number of different products, each with narrow indications and a lack of flexibility for various age groups of patients2.  The consequence of this is the widespread use of melatonin products outside their licensed indications, and unlicensed practices such as the crushing of tablets3,4.

An unprecedented range of licensed indications and use across age groups will make CEYESTO® Oral Solution an attractive and flexible option for policy makers and prescribers looking to simplify their use of melatonin products1.  

Importantly, ALTURiX have also chosen to redefine the cost to the NHS of oral liquid melatonin products by pricing CEYESTO® Oral Solution at £25.65 for 150ml5.  At 80% less expensive than the current Drug Tariff pricing for other liquid melatonin preparations, this could save the NHS up to £23m each year in melatonin prescribing costs at a time when the NHS is under significant financial pressure6.

Specifically, in addition to the standard short term treatment of jet lag in adults1, CEYESTO® Oral Solution has also been approved for use in:

  • Delayed sleep wake phase disorder (DSWPD) in children and adolescents aged 6-17 years and adults up to 25 years of age, where sleep hygiene measures have been insufficient1. (A world-first indication)
  • Insomnia in children and adolescents aged 6-17 years with attention deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been insufficient1.
  • Single use for short-term sedation under medical supervision to facilitate electroencephalograms (EEGs) in children and adolescents from 1 to 18 years1. (A world-first indication)

Although treatment can not be started in adults with DSWPD or Insomnia with ADHD, in another world first, CEYESTO® Oral Solution can continue to be used in adults where  symptoms persist and if clear benefit has been shown from treatment1

Read more…

Latest articles